Braveheart Bio

About Braveheart Bio

Braveheart Bio is dedicated to transforming the care of hypertrophic cardiomyopathy (HCM) and related conditions, aiming to deliver better outcomes and quality of life for patients.

Products & Services

Investigational Treatment for HCM:An investigational treatment in late-stage clinical development targeting the underlying mechanisms of hypertrophic cardiomyopathy to improve heart performance.

Specialties

Hypertrophic Cardiomyopathy (HCM) treatment Cardiac muscle performance improvement Clinical development of investigational therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 185000000 MR: - FA: 185 million FAN: 185000000	D: 2025-11-05 FD: 2025-11-05	5 investors

Series A Latest

2025-11-05

$185.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Travis Murdoch, MD

Chief Executive Officer and President

M

Michele Anderson

Chief Development Officer

P

Paul Rickey

Chief Financial Officer

M

Marc Evanchik, MS

Senior Vice President of Pharmacology and Translational Medicine

N

Natalie Dement, JD

Vice President, Head of Legal

A

Amy Feng, PhD

Vice President of Biometrics and Data Management

View 14 more team members with Pro

Unlock Full Team Directory

Recent News

Braveheart Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised